Last reviewed · How we verify

NCT06080711: AIDMel

AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy

Status unknown NA Last updated 12 October 2023
What this trial tests

NA trial testing AI assistance in Skin Cancer in 30 participants. Status unknown.

Timeline
15 February 2023
Primary endpoint
30 June 2024
30 October 2024

Quick facts

Lead sponsorKarolinska University Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposediagnostic
Enrollment30
Start date15 February 2023
Primary completion30 June 2024
Estimated completion30 October 2024
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska University Hospital

Who can join

18 and older, any sex, with Skin Cancer or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study an artificial intelligence (AI) tool for skin cancer diagnosis is implemented in a teleldermatoscopy platform. The aim is to study the effects on clinician diagnostic accuracy, management decisions, and confidence. Furthermore, this prospective randomized study investigates the role of human factors in determining clinician reliance on AI tools and the consequent accuracy in a real-world setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Skin Cancer

Currently open trials in the same condition.

Other Karolinska University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06080711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing